Control of ACAT2 Liver Expression by HNF4{alpha}. Lesson From MODY1 Patients.
(2009) In Arteriosclerosis, Thrombosis and Vascular Biology 29(8). p.1235-1241- Abstract
- OBJECTIVE: ACAT2 is thought to be responsible for cholesteryl ester production in chylomicron and VLDL assembly. Recently, we identified HNF1alpha as an important regulator of the human ACAT2 promoter. Thus, we hypothesized that MODY3 (HNF1alpha gene mutations) and possibly MODY1 (HNF4alpha, upstream regulator of HNF1alpha, gene mutations) subjects may have lower VLDL esterified cholesterol. METHODS AND RESULTS: Serum analysis and lipoprotein separation using size-exclusion chromatography were performed in controls and MODY1 and MODY3 subjects. In vitro analyses included mutagenesis and cotransfections in HuH7 cells. Finally, the relevance in vivo of these findings was tested by ChIP assays in human liver. Whereas patients with MODY3 had... (More)
- OBJECTIVE: ACAT2 is thought to be responsible for cholesteryl ester production in chylomicron and VLDL assembly. Recently, we identified HNF1alpha as an important regulator of the human ACAT2 promoter. Thus, we hypothesized that MODY3 (HNF1alpha gene mutations) and possibly MODY1 (HNF4alpha, upstream regulator of HNF1alpha, gene mutations) subjects may have lower VLDL esterified cholesterol. METHODS AND RESULTS: Serum analysis and lipoprotein separation using size-exclusion chromatography were performed in controls and MODY1 and MODY3 subjects. In vitro analyses included mutagenesis and cotransfections in HuH7 cells. Finally, the relevance in vivo of these findings was tested by ChIP assays in human liver. Whereas patients with MODY3 had normal lipoprotein composition, those with MODY1 had lower levels of VLDL and LDL esterified cholesterol, as well as of VLDL triglyceride. Mutagenesis revealed one important HNF4 binding site in the human ACAT2 promoter. ChIP assays and protein-to-protein interaction studies showed that HNF4alpha, directly or indirectly (via HNF1alpha), can bind to the ACAT2 promoter. CONCLUSIONS: We identified HNF4alpha as an important regulator of the hepatocyte-specific expression of the human ACAT2 promoter. Our results suggest that the lower levels of esterified cholesterol in VLDL- and LDL-particles in patients with MODY1 may-at least in part-be attributable to lower ACAT2 activity in these patients. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1411897
- author
- Pramfalk, C ; Karlsson, E ; Groop, Leif LU ; Rudel, L L ; Angelin, B ; Eriksson, M and Parini, P
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Arteriosclerosis, Thrombosis and Vascular Biology
- volume
- 29
- issue
- 8
- pages
- 1235 - 1241
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- wos:000268007500014
- pmid:19478207
- scopus:68149170609
- ISSN
- 1524-4636
- DOI
- 10.1161/ATVBAHA.109.188581
- language
- English
- LU publication?
- yes
- id
- 530a0579-0355-4832-84bd-05b9f92baea7 (old id 1411897)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19478207?dopt=Abstract
- date added to LUP
- 2016-04-01 11:40:17
- date last changed
- 2024-01-07 16:06:16
@article{530a0579-0355-4832-84bd-05b9f92baea7,
abstract = {{OBJECTIVE: ACAT2 is thought to be responsible for cholesteryl ester production in chylomicron and VLDL assembly. Recently, we identified HNF1alpha as an important regulator of the human ACAT2 promoter. Thus, we hypothesized that MODY3 (HNF1alpha gene mutations) and possibly MODY1 (HNF4alpha, upstream regulator of HNF1alpha, gene mutations) subjects may have lower VLDL esterified cholesterol. METHODS AND RESULTS: Serum analysis and lipoprotein separation using size-exclusion chromatography were performed in controls and MODY1 and MODY3 subjects. In vitro analyses included mutagenesis and cotransfections in HuH7 cells. Finally, the relevance in vivo of these findings was tested by ChIP assays in human liver. Whereas patients with MODY3 had normal lipoprotein composition, those with MODY1 had lower levels of VLDL and LDL esterified cholesterol, as well as of VLDL triglyceride. Mutagenesis revealed one important HNF4 binding site in the human ACAT2 promoter. ChIP assays and protein-to-protein interaction studies showed that HNF4alpha, directly or indirectly (via HNF1alpha), can bind to the ACAT2 promoter. CONCLUSIONS: We identified HNF4alpha as an important regulator of the hepatocyte-specific expression of the human ACAT2 promoter. Our results suggest that the lower levels of esterified cholesterol in VLDL- and LDL-particles in patients with MODY1 may-at least in part-be attributable to lower ACAT2 activity in these patients.}},
author = {{Pramfalk, C and Karlsson, E and Groop, Leif and Rudel, L L and Angelin, B and Eriksson, M and Parini, P}},
issn = {{1524-4636}},
language = {{eng}},
number = {{8}},
pages = {{1235--1241}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{Arteriosclerosis, Thrombosis and Vascular Biology}},
title = {{Control of ACAT2 Liver Expression by HNF4{alpha}. Lesson From MODY1 Patients.}},
url = {{http://dx.doi.org/10.1161/ATVBAHA.109.188581}},
doi = {{10.1161/ATVBAHA.109.188581}},
volume = {{29}},
year = {{2009}},
}